You are here

Gilead targets remdesivir supply for 2 million Covid-19 patients by year-end

nz_gilead_230660.jpg
Gilead Sciences Inc said on Monday it expects to be able to supply enough of its antiviral drug remdesivir by year end to treat more than 2 million Covid-19 patients, more than double its previous target of 1 million.

[BENGALURU] Gilead Sciences Inc said on Monday it expects to be able to supply enough of its antiviral drug remdesivir by year end to treat more than 2 million Covid-19 patients, more than double its previous target of 1 million.

The company also said it hoped to start trials in August of...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes